newsfilter
← Latest News
Business Wire·

Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs

  • Turn Therapeutics, Inc. (NASDAQ: TTRX) appointed Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs.
  • Dr. Redfield, the former 18th Director of the CDC, will provide strategic guidance on the clinical development, public health implications, and regulatory positioning of GX-03.
  • GX-03 is a first-in-class, non-systemic topical inhibitor currently in Phase 2 clinical trials for moderate-to-severe atopic dermatitis.
  • CEO Brad Burnam stated Dr. Redfield's expertise will be instrumental in accelerating the regulatory path to patients.
  • Dr. Redfield emphasized his commitment to supporting the rapid advancement of GX-03 to address unmet needs for inflammatory skin conditions.
  • Turn Therapeutics focuses on developing precision therapies targeting underlying causes of inflammatory diseases with high unmet needs.
  • The press release includes forward-looking statements subject to risks regarding development timelines, registration effectiveness, and strategic execution.